Illumina ILMN
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Illumina (ILMN) Business Model and Operations Summary
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Key Insights
Illumina (ILMN) Core Market Data and Business Metrics
Latest Closing Price
$78.39Market Cap
$12.38 BillionPrice-Earnings Ratio
-10.19Total Outstanding Shares
158.40 Million SharesTotal Employees
8,970Dividend
No dividendIPO Date
July 28, 2000SIC Description
Laboratory Analytical InstrumentsPrimary Exchange
NASDAQHeadquarters
5200 Illumina Way, San Diego, CA, 92122
Historical Stock Splits
If you bought 1 share of ILMN before September 23, 2008, you'd have 2 shares today.
| Execution Date | Split Amount |
|---|---|
| September 23, 2008 | 2-for-1 |
Cash Flow Statement
January 1, 2024 to December 29, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $837 Million |
| Net Cash Flow From Financing Activities, Continuing | $-570 Million |
| Net Cash Flow | $79 Million |
| Net Cash Flow From Investing Activities, Continuing | $-178 Million |
| Net Cash Flow From Financing Activities | $-570 Million |
| Exchange Gains/Losses | $-10 Million |
Income Statement
January 1, 2024 to December 29, 2024
| Metric | Value |
|---|---|
| Preferred Stock Dividends And Other Adjustments | $0 |
| Operating Income/Loss | $-833 Million |
| Diluted Average Shares | $159 Million |
| Costs And Expenses | $5.55 Billion |
| Net Income/Loss | $-1.22 Billion |
| Basic Earnings Per Share | $-7.69 |
Comprehensive Income
January 1, 2024 to December 29, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-1.20 Billion |
| Other Comprehensive Income/Loss | $-1.20 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-1.20 Billion |
Balance Sheet
January 1, 2024 to December 29, 2024
| Metric | Value |
|---|---|
| Other Non-current Assets | $2.45 Billion |
| Liabilities | $3.93 Billion |
| Inventory | $547 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Wages | $252 Million |
| Liabilities And Equity | $6.30 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||